Alan W. Partin, MD, PhD

home / authors / alan-w-partin-md-phd

Articles

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

September 1st 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 1

Alan W. Partin, MD, PhD;Gerald E. Hanks, MD;Eric A. Klein, MD;Judd W. Moul, MD;William G. Nelson, MD, PhD;Howard I. Scher, MD

August 1st 2002

Nomograms That May Aid in Treatment Decisions

Alan W. Partin, MD, PhD

November 1st 1997

Data from three academic institutions were used to develop a model to predict pathologic stage in a group of men with clinically localized prostate cancer. The model combined serum prostate-specific antigen (PSA) level, clinical stage, and Gleason score. The data were used to generate nomograms that present the probability of a patient having organ-confined cancer, isolated capsular penetration, seminal vesicle involvement, or pelvic lymph node involvement. [Oncol News Int 6(Suppl 3):14-15, 1997]

Prostate-Specific Antigen: What’s New in 1997

Jürgen Pannek, MD;Alan W. Partin, MD, PhD

September 1st 1997

When used alone, prostate-specific antigen (PSA) is not sufficiently sensitive or specific to consider it an ideal tool for the early detection or staging of prostate cancer. To optimize the use of PSA, the concepts of PSA velocity,